Wednesday, July 8, 2026

Patent intelligence · US

US 11122832

Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise

granted A61PA61P1/04A61P13/12A61P21/00
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 15
Applicant portfolio 121
Patent details — US 11122832
Jurisdiction
US
Status
granted
Grant date
Sep 21, 2021
Expiration
Sep 16, 2041
Claims
38
CPC classes
A61P, A61P1/04, A61P13/12, A61P21/00
View on Google Patents ↗

Quick answer

US 11122832 (Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise) is held by Nature's Sunshine Products, Inc.. Status: granted. Granted Sep 21, 2021. Expires Sep 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
38
CPC classes
A61P, A61P1/04, A61P13/12, A61P21/00, A61P25/28, A61P29/00

More from Nature's Sunshine Products, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12428432

    Thienopyrimidine derivatives having stereo configurations and use thereof in medicine

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  2. US 12428389

    Diarylamide compound and application thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  3. US 12384853

    Anti-HER2/PD1 bispecific antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Aug 7, 2045

    granted
  4. US 12324812

    Glucopyranosyl derivatives and their uses

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Jun 5, 2045

    granted
  5. US 12319748

    Antibody binding to human HER2 and preparation method and use thereof

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires May 29, 2045

    granted
  6. US 12312348

    RET inhibitors, pharmaceutical compositions and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires May 22, 2045

    granted
  7. US 12269886

    Tetravalent bispecific antibody against PD-1 and PD-L1

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Apr 3, 2045

    granted
  8. US 12258317

    Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Mar 20, 2045

    granted

Frequently asked questions

What is US patent 11122832?

US 11122832 (Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise) is held by Nature's Sunshine Products, Inc.. Status: granted. Granted Sep 21, 2021. Expires Sep 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11122832?

Nature's Sunshine Products, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.

When does US 11122832 expire?

Our index shows an expiration date of Sep 16, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.